Canadian Blood Services
BLOOD PLASMA STEM CELLS ORGANS & TISSUES

1800 Alta Vista Drive
Ottawa ON
K1G 4J5
Canada

ACTION REQUIRED

Revised Designated PPRP Request Form and Requesting Emicizumab for Expanded Criteria

Customer Letter # 2021-39

2021-10-18

Dear Colleagues:

As shared in CL 2021-34, Canadian Blood Services has received approval to expand access to emicizumab (Hemlibra®) to individuals with severe congenital hemophilia A (intrinsic factor VIII level < 1%) without inhibitors. The revised *Request for Patient Designated Plasma Protein and Related Products* form will be available on October 18, 2021 to request access to emicizumab.

Requesting emicizumab

Canadian Blood Services is committed to making emicizumab available to all eligible patients as soon as possible. It is difficult to predict the rate at which emicizumab utilization will increase. Over the coming weeks, we will be building up our inventory and monitoring volumes closely to ensure current patient supply is maintained while new patients are initiated. Depending on the volume of requests, the review may take up to 30-days to provide time to balance the supply with demand. As a reminder, please consider the stock of alternate therapies in the patients' homes when starting emicizumab to avoid wastage and outdating.

To avoid a backlog of requests and support a gradual uptake, we are asking treaters to review their eligible patients and attempt to stagger their starts based on clinical priority (e.g., those requiring emicizumab within 1-3 months, 3-6 months, or 6+ months). Additionally, we encourage customers to submit request forms as soon as possible with a future start date noted under *Date of Next Pick-Up* to help with planning for both clinics and Canadian Blood Services.

Changes to Request Form

Canadian Blood Services has made several changes to the *Request for Patient Designated Plasma Protein and Related Products* form. The request form now includes patients' personal information, including clinical data. This information is necessary to enable us to:

1. Adjudicate product requests to ensure that appropriate patients are provided access to these products.
2. Communicate with treaters and transfusion medicine departments.
3. Monitor trends in utilization and more accurately forecast demand, at an aggregate level.

The *Privacy Notice for Patient Designated Plasma Protein and Related Products* has been developed for treaters to provide to their patients so that patients understand what personal information will be collected, the purposes for the collection and how it will be used, disclosed, and retained by Canadian Blood Services. The Privacy Notice will be posted in two places:

1. The Privacy/Legal page of the Canadian Blood Services website, and;
2. The Submitting Product Orders page will have a link to the notice.

A *Frequently Asked Questions* document has also been created to answer questions about these changes and provide details on how to complete the updated request form (see attached).

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the “Hospitals Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,



Sylvain Grenier,
Director, Plasma Protein and Related Products Formulary Program